معرفی
Dr. Yansheng Liu is an Associate Professor in the Department of Pharmacology at Yale University School of Medicine and a secondary faculty member in the Department of Biomedical Informatics & Data Science (BIDS). He is also a Member of both the Yale Cancer Biology Institute and the Yale Cancer Center, where he leads a research group specializing in quantitative proteomics with a focus on cancer biology and systems biology.
Dr. Liu earned his Ph.D. in Biomedical Sciences from the Chinese Academy of Sciences in 2011 and completed postdoctoral training at ETH Zurich under the mentorship of Ruedi Aebersold. Since joining Yale's faculty in December 2017, his research has centered on analyzing protein turnover and post-translational modifications to unravel the complexities of cancer aneuploidy, cellular signaling pathways, and biodiversity.
His research program spans three main areas:
- Impact of Post-Translational Modifications on Protein Stability: Developed the DeltaSILAC method to quantify phosphorylation effects on protein turnover, revealing phosphorylation often reduces protein stability—a previously underappreciated phenomenon with implications for Alzheimer's and cancer
- Understanding Biodiversity and Cancer Aneuploidy: Led multi-laboratory investigations uncovering HeLa cell aneuploidy heterogeneity (Nature Biotechnology 2019) and expanded to 11 mammalian species (Science Advances 2022), identifying phosphorylation co-evolution networks and RNA metabolism variations
- Advanced Mass Spectrometry Development: Created innovative methods including RTwinDIA, BoxCarmax-DIA, and NAguideR for missing-value imputation, plus state-of-the-art MALDI imaging for spatial omics at single-cell resolution
Dr. Liu's publication record demonstrates exceptional productivity with numerous high-impact papers in Cell, Nature, and Science. His recent work shows increasing translational focus, particularly on protein turnover mapping across tissues and brain regions (Cell 2025) with direct implications for neurodegenerative diseases and cancer treatment. The research consistently integrates quantitative proteomics with clinical applications.
His scientific achievements have been recognized with multiple prestigious awards:
- US HUPO Robert J. Cotter Award (2023)
- HUPO Early Career Researcher Award (2021)
- ASMS Research Award (2021)
- Career Enhancement Program (CEP) award from Yale SPORE in Lung Cancer (2021)
- Early Career Faculty Award from ASBMB (2021)
Dr. Liu actively collaborates with over 35 Yale laboratories, with Wenxue Li (34 publications), Barbora Salovska (15 publications), and Yi Di (5 publications) as his most frequent collaborators. His lab has developed robust proteomics platforms that integrate DIA-MS with cancer models and clinical samples to uncover fundamental principles of proteome dynamics in health and disease. Current work focuses on identifying universal quantitative rules governing proteome variability across individuals and species, with direct applications to precision medicine.
The Yansheng Liu Lab at Yale's West Campus Advanced Biosciences Center utilizes cutting-edge MALDI mass spectrometry imaging for spatial omics studies at tissue and single-cell levels. Their research bridges basic proteome dynamics with clinical applications, particularly in cancer and neurodegenerative diseases, demonstrating how protein turnover mapping may offer novel therapeutic insights for Alzheimer's and cancer treatment as highlighted in recent news coverage.
